Mayo Clinic launching 4 startups with healthcare partners

Mayo Clinic’s immersive program for health tech startups has launched its initial cohort of companies, starting with four AI startups.

The program, Mayo Clinic Platform_Accelerate, is 20 weeks in length and aims to get the four companies market ready. Mayo Clinic has partnered with Epic and Google in the program, with the two companies offering workshops for the participants. The companies in the program will have access to Mayo Clinic experts in regulatory, clinical, technology and business domains with a focus on AI model validation and clinical readiness.

The four companies include:

  • Cliexa –– a Denver-based AI company that aims to transform patient-centered data into actionable insights for people with cardiovascular conditions and multiple chronic diseases.
     
  • Quadrant Health –– Based in New York, Quadrant Health analyzes electronic health record information and patient messaging to triage patients and predict patient harm.
     
  • ScienceIO –– Based in Boston and New York, this AI company will develop tools for organizing data to streamline care and reduce administrative burdens.
     
  • Seer Medical –– A Melbourne, Australia-based company that will use data to refine and test its home-based epilepsy diagnostics and management models.

The four companies were chosen from a competitive process, and each aims to improve healthcare in their own way.

Find more news on healthcare's digital transformation

"Health tech startups are critical contributors to the cycle of innovation," John Halamka, MD, president of Mayo Clinic Platform, said in a statement. "We are excited to collaborate with these innovators to solve some of the most complex problems in medicine today."

While the March 2022 cohort group is underway, a waitlist is open for the second Mayo Clinic Platform_Accelerate cohort, expected to begin summer 2022. 

"We are helping participants take a crucial step in their growth trajectory by providing startups with a disciplined focus on model validation and clinical readiness to show product value," Eric Harnisch, vice president of partner programs for Mayo Clinic Platform, said in a press release. "The program is integral to our Mayo Clinic Platform mission to enable new knowledge, new solutions and new technologies that improve patients' lives worldwide."

The announcement of the first cohort comes after Mayo Clinic reported $1.2 billion profits in 2021 –– up 66% from 2020.

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.